
Global leader in digital imaging for Pathology & Cytogenetics. AI-driven, probe & scanner-agnostic platforms advancing diagnostic accuracy. A @ZYTOMICS company.
Carlsbad
Joined January 2012
- Tweets2.4K
- Following507
- Followers281
- Likes118
ASI | a ZYTOMICS company retweeted
"Our collaboration with @ASImaging represents ARUP’s commitment to embracing the most modern technologies in clinical diagnostics.”—Dr. Salama on #PathFusion. More on our blog: bit.ly/2AborEl
ASI | a ZYTOMICS company retweeted
Learn more about PathFusion, the cutting-edge result of our collaboration with @ASImaging: bit.ly/2zMfgrT
ASI | a ZYTOMICS company retweeted
It’s International Pathology Day! Because without pathology, there is no medicine. ow.ly/1itm30gnJmp #PathologyDay
ASI | a ZYTOMICS company retweeted
Replying to @ASImaging
@ASImaging's HiPath IHC imaging & analysis system provides PD-L1 interpretation. Visit #ASCP2017 booth 913. appliedspectralimaging.com/
ASI | a ZYTOMICS company retweeted
#CAPACP2017 drop by our booth and check out our Hi-Path for PD-L1 Analysis @ASImaging @Bobbijo_Shirley
ASI | a ZYTOMICS company retweeted
Christmas. Microbiology style! Made by Scientists at the J. Craig Venter institute!!
#merrychristmas #agarplate
ASI | a ZYTOMICS company retweeted
Hands on training in microscopy at GCCRD workshop, thanks to @ASImaging @zeiss_micro @umanitoba @CancerCareMBFdn
ASI | a ZYTOMICS company retweeted
#ICYMI: Current blood cancer drug prices not justified, MD Anderson study finds: bit.ly/1GxduFa #leusm #lymsm #endcancer
ASI | a ZYTOMICS company retweeted
9 Wilms’ tumor symptoms: bit.ly/1FZ3xju @kidsandcancer #endcancer
ASI | a ZYTOMICS company retweeted
Digital Pathology Market All Set To Grow To $692.5 Million By 2022: Latest Report By Grand View .. - goo.gl/alerts/D0XC #GoogleAlerts
ASI | a ZYTOMICS company retweeted
Dr. Leibovich, a urologic oncologist at @MayoClinic, discusses evaluation, diagnosis, treatment of testicular cancer atjo.es/2Bkf
ASI | a ZYTOMICS company retweeted
Breast-feeding may cut breast cancer recurrence risk.
nyti.ms/1cxmoey





















